Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice

Alessandro Mattè; Penelope A Kosinski; Enrica Federti; Lenny Dang; Antonio Recchiuti; Roberta Russo; Angela Siciliano; Veronica Riccardi; Anne Janin; Matteo Mucci; Christophe Leboeuf; Achille Iolascon; Carlo Brugnara; Lucia De Franceschi

doi:10.3324/haematol.2022.282614

Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice

Haematologica. 2023 Sep 1;108(9):2535-2541. doi: 10.3324/haematol.2022.282614.

Affiliations

¹ University of Verona and AOUI Verona, Verona.
² Agios Pharmaceuticals, Inc., Cambridge, MA.
³ Dept. of Medical, Oral and Biotechnology Science, "G. d'Annunzio" University of Chieti, Chieti.
⁴ Dept. of Molecular Medicine and Medical Biotechnology and CEINGE, University of Naples Federico II, Naples.
⁵ University Diderot of Paris, Paris.
⁶ Department of Laboratory Medicine, Harvard Medical School, Boston Children's Hospital, Boston, MA (USA).
⁷ University of Verona and AOUI Verona, Verona. lucia.defranceschi@univr.it.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Iron
Iron Overload* / drug therapy
Iron Overload* / etiology
Mice
Piperazines
Pyruvate Kinase
beta-Thalassemia* / therapy

Substances

mitapivat
Pyruvate Kinase
Iron
Piperazines

Grants and funding

Funding: This study was supported by an Agios Pharmaceuticals, Inc. research collaborative grant to LDF. Editorial assistance was provided by Avant Healthcare, LLC and Excel Medical Affairs, Horsham, UK, supported by Agios.